CRISPRGuard is a smart program that helps scientists create antiviral CRISPR designs. Upload virus genomes, find conserved targets, and verify safety against the human genome.
The problem
For pathogens like dengue, rabies, and herpes, medicine mostly offers vaccines or lifelong symptomatic treatment — not targeted, designable antivirals that keep up with mutations.
The solution
An online platform with a simple interface and working code. Upload virus genomes and mutations — get conserved targets, positions, and human-safety checks in a ready table.
Works across viral families — including hard-to-treat pathogens where classic drugs fall short.
Every candidate sequence is checked against the human genome. Safety is a first-class filter, not an afterthought.
From NCBI multi-genome input to ranked gRNA tables — built for chemists and biotech teams who need speed.
Therapeutic concept
Guides designed by CRISPRGuard feed into a known modality stack: mRNA-encoded Cas, guide RNA, and lipid nanoparticle (or similar) delivery — aligned with clinical CRISPR precedents.
A tablet or injection delivers a lipid envelope with CRISPR-Cas mRNA and guide RNA. Inside the cell, mRNA is translated; Cas binds the guide and forms a complex that can stay active for an extended stability window (up to ~10 days). If a virus enters in that window, viral nucleic acid is cut before replication.
First CRISPR medicines are already approved (e.g. Casgevy). In vivo LNP programs such as NTLA-2001 and related trials show deep target knockdown in humans — the delivery and safety story for CRISPR is no longer theoretical.
Already done
We are not only a slide deck — the pipeline has been run on major human-pathogenic virus sets.
Filovirus platform
Targeting all human-transmitted strains across Zaire, Sudan, Bundibugyo, Bombali, and Marburg subgroups.
Dengue
NCBI Virus dengue set analyzed for Cas13b guide targets: 4,850 genomes total, of which 4,344 are human-associated strains.
Market
Governments and pharma already spend billions on pandemic prep — but universal design tools remain underinvested.
Global antiviral drug market value in 2024
Projected market size by 2035
Example: U.S. HHS investment in oral COVID antivirals
Business model
Compute-as-service for institutes, partnerships with DNA-therapy pharma, and IP share on real drugs.
Calculations and new molecule designs on request — tailored to viral mutations and prevalence.
Collaborate with companies building nucleic-acid medicines who need conserved, safe viral targets.
If a real drug is obtained: from ~1% of profit (~$175M scenario). If trials fail: $500K–$1M floor structures.
Pre-seed — $300K · Target path via Trendlines and strategic pharma / CRISPR ecosystem partners (Pfizer, Roche/Genentech, Novartis, Gilead, Moderna, Intellia, Mammoth, BARDA/CEPI-class orgs, and others).
Team
Young chemists and builders, guided by PhD-level science.
Bio-Technology student. Leads product vision, platform, and company building.
Owns product direction and partner-facing execution.
Scientific guidance on chemistry and experimental rigor.
Get in touch
Looking for research partners, pilot genome projects, and pre-seed investors. Happy to walk through the pipeline, filovirus / dengue results, and roadmap.